COMMUNIQUÉS West-GlobeNewswire
-
Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises” for AI‑Powered Chronic Disease Services
19/05/2026 -
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
19/05/2026 -
Rapid Nutrition Advances Finalization of Australian Flagship Initiative
19/05/2026 -
Pennant Group to Participate in the 2026 RBC Global Healthcare Conference
19/05/2026 -
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
18/05/2026 -
Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans le DAAT
18/05/2026 -
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
18/05/2026 -
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
18/05/2026 -
Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
18/05/2026 -
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026 -
Certara to Participate in Upcoming Investor Conferences
18/05/2026 -
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
18/05/2026 -
Memopezil Claims Evaluated (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
18/05/2026 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18/05/2026 -
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026 -
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
18/05/2026 -
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
18/05/2026 -
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05/2026 -
Pennant Announces an Acquisition of Senior Living Community in Arizona
18/05/2026
Pages